OS and PFS of patients with MDS according to IPSS-R and WT1 and PRAME transcript levels. Patients with MDS were grouped according to favorable (low WT1 or low PRAME) or adverse (high WT1 or high PRAME) expression profiles. Therefore, the proposed score was drawn up by assigning a value of 0 for each gene expressing a favorable RNA level and a value of 1 for each gene with an adverse expression profile. OS (A) and PFS (D) of patients with MDS based on IPSS-R. OS (B) and PFS (E) of patients with MDS based on WT1/PRAME score. It distinguished 3 subsets of patients with different OS (P < .001) and PFS (P < .001). The OS and PFS for patients with both WT1 and PRAME overexpression were significantly lower than that those for patients with either WT1 or PRAME overexpression (P = .013 for OS; P = .001 for PFS, respectively). OS (C) and PFS (F) of patients with MDS in the next-highest IPSS risk group is included for the purpose of comparison, P values were calculated between low-risk patients with WT1/PRAME overexpression and intermediate patients.